Amneal Pharmaceuticals
AMRX
129 hedge funds and large institutions have $756M invested in Amneal Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 58 closing their positions.
84% more call options, than puts
Call options by funds: $875K | Put options by funds: $476K
2% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.23% less ownership
Funds ownership: 94.45% → 91.22% (-3.2%)
21% less funds holding
Funds holding: 164 → 129 (-35)
51% less capital invested
Capital invested by funds: $1.55B → $756M (-$791M)
57% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.2M |
| 3 |
Neuberger Berman Group
New York
|
+$8.94M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.89M |
| 5 |
Millennium Management
New York
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$33.8M |
| 2 |
TG
TCW Group
Los Angeles,
California
|
-$32.6M |
| 3 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$25.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.2M |
AMRX Hedge Fund Activity: Q2 2019 in Review
129 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2019, worth a combined $756M — down 51% from $1.55B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of AMRX and 25 opened new positions — a net loss of 33 holders — while 41 trimmed existing stakes and 42 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $33.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $33.8M sold.
- 129 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2019, down from 164 in Q1 2019.
- Funds reported $756M of Amneal Pharmaceuticals stock for Q2 2019, down 51% quarter-over-quarter.
- 25 funds opened new Amneal Pharmaceuticals positions in Q2 2019 and 58 closed out, a net change of -33 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2019 was Point72 Asset Management, an estimated $33.9M added.
- The largest Amneal Pharmaceuticals seller in Q2 2019 was Janus Henderson Group, an estimated $33.8M sold.
Based on aggregated 13F filings for Q2 2019.